Profile image
Research Associate

Dr Arunasingam Abayasingam

BSc (Honours)

Viral Immunology Systems Program
Phone
+61 (2) 9348 1583
E-mail
aabayasingam@kirby.unsw.edu.au
Underwood AP; Gupta M; Wu B-R; Eltahla AA; Boo I; Wang JJ; Agapiou D; Abayasingam A; Reynaldi A; Keoshkerian E; Zhao Y; Brasher N; Walker MR; Bukh J; Maher L; Gordon T; Davenport MP; Luciani F; Drummer HE; Lloyd AR; Bull RA, 2024, 'B cell characteristics define HCV reinfection outcome.', J Hepatol, http://dx.doi.org/10.1016/j.jhep.2024.04.004
2024
Adhikari A; Abayasingam A; Brasher NA; Kim HN; Lord M; Agapiou D; Maher L; Rodrigo C; Lloyd AR; Bull RA; Tedla N, 2024, 'Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes', Journal of Medical Virology, 96, http://dx.doi.org/10.1002/jmv.29381
2024
Underwood AP; Gupta M; Wu B-R; Eltahla AA; Boo I; Wang JJ; Agapiou D; Abayasingam A; Reynaldi A; Keoshkerian E; Zhao Y; Brasher N; Walker MR; Bukh J; Maher L; Gordon T; Davenport M; Luciani F; Drummer HE; Lloyd AR; Bull RA, 2023, 'B Cell Signatures and Antibody Imprinting Define HCV Reinfection Outcome', , http://dx.doi.org/10.2139/ssrn.4418620
2023
Norton T; Lynn MA; Rossouw C; Abayasingam A; Perkins G; Hissaria P; Bull RA; Lynn DJ, 2023, 'B and T cell responses to the BNT162b2 COVID-19 mRNA vaccine are not impaired in germ-free or antibiotic-treated mice.', Gut, http://dx.doi.org/10.1136/gutjnl-2023-329810
2023
Ryan FJ; Norton TS; McCafferty C; Blake SJ; Stevens NE; James J; Eden GL; Tee YC; Benson SC; Masavuli MG; Yeow AEL; Abayasingam A; Agapiou D; Stevens H; Zecha J; Messina NL; Curtis N; Ignjatovic V; Monagle P; Tran H; McFadyen JD; Bull RA; Grubor-Bauk B; Lynn MA; Botten R; Barry SE; Lynn DJ, 2023, 'A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines', Cell Reports Medicine, 4, http://dx.doi.org/10.1016/j.xcrm.2023.100971
2023
Garcia-Valtanen P; Hope CM; Masavuli MG; Yeow AEL; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Bouras G; Gummow J; Ferguson C; O'Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Kok-Lim C; Beard MR; Weiskopf D; Sette A; Turville SG; Bull RA; Barry SC; Grubor-Bauk B, 2022, 'SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents', Cell Reports Medicine, 3, http://dx.doi.org/10.1016/j.xcrm.2022.100651
2022
Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Lloyd AR; Kaldor J; Dore G; Sorrell T; Hudson B; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Lloyd AR; Sultan R; Hudson B; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272
2022
Rouet R; Mazigi O; Walker GJ; Langley DB; Sobti M; Schofield P; Lenthall H; Jackson J; Ubiparipovic S; Henry JY; Abayasingam A; Burnett D; Kelleher A; Brink R; Bull RA; Turville S; Stewart AG; Goodnow CC; Rawlinson WD; Christ D, 2021, 'Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies', mAbs, 13, http://dx.doi.org/10.1080/19420862.2021.1922134
2021
Abayasingam A; Balachandran H; Agapiou D; Hammoud M; Rodrigo C; Keoshkerian E; Li H; Brasher NA; Christ D; Rouet R; Burnet D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Stella AO; Fichter C; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Tea F; Pilli D; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA; Burnett D, 2021, 'Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection', Cell Reports Medicine, 2, pp. 100228, http://dx.doi.org/10.1016/j.xcrm.2021.100228
2021
Rouet R; Mazigi O; Walker G; Langley D; Sobti M; Schofield P; Lenthall H; Jackson J; Ubiparipovic S; Henry J; Abayasingam A; Burnett D; Kelleher A; Brink R; Bull R; Turville S; Stewart A; Goodnow C; Rawlinson W; Christ D, 2020, 'Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies', , http://dx.doi.org/10.1101/2020.12.14.422791
2020
Abayasingam A; Leung P; Eltahla A; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd A; Rodrigo C, 2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection, Genetics and Evolution, 71, pp. 36 - 41, http://dx.doi.org/10.1016/j.meegid.2019.02.032
2019
Walker MR; Leung P; Eltahla AA; Underwood A; Abayasingam A; Brasher NA; Li H; Wu BR; Maher L; Luciani F; Lloyd AR; Bull RA, 2019, 'Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies', Scientific Reports, 9, pp. 13300, http://dx.doi.org/10.1038/s41598-019-49454-w
2019
Adhikari A; Abayasingam A; A NB; Kim HN; Lord M; Agapiou D; Maher L; Rodrigo C; Lloyd A; Bull R; Tedla N, 2023, Characterisation of antibody dependent cellular phagocytosis in patients infected with Hepatitis C virus with different clinical outcomes, , http://dx.doi.org/10.22541/au.168992839.95818489/v1
2023
Ryan FJ; Norton TS; McCafferty C; Blake SJ; Stevens NE; James J; Eden GL; Tee YC; Benson SC; Masavuli MG; Yeow AEL; Abayasingam A; Agapiou D; Stevens H; Zecha J; Messina NL; Curtis N; Ignjatovic V; Monagle P; Tran H; McFadyen JD; Bull RA; Grubor-Bauk B; Lynn MA; Botten R; Barry SE; Lynn DJ, 2022, A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses, , http://dx.doi.org/10.1101/2022.09.22.22280180
2022
Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher N; Madushan Fernando BS; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post J; Hudson B; Gilroy N; Bartlett A; Ahlenstiel G; Grubor-Bauk B; Dwyer D; Konecny P; Lloyd A; Martinello M; Bull R; Tedla N, 2021, Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection, , http://dx.doi.org/10.1101/2021.12.21.473774
2021
Garcia-Valtanen P; Hope C; Masavuli M; Lip Yeow AE; Balachandran H; Mekonnen Z; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Gummow J; Ferguson C; O’Connor S; McCartney E; Lynn D; Maddern G; Gowans E; Reddi BAJ; Shaw D; Kok-Lim C; Turville S; Beard M; Weiskopf D; Sette A; Bull R; Barry S; Grubor-Bauk B, 2021, COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection, , http://dx.doi.org/10.1101/2021.11.08.21266035
2021
Bull R; Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post J; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd A; Martinello M, 2020, Long-term persistence of neutralizing memory B cells in SARS-CoV-2, , http://dx.doi.org/10.21203/rs.3.rs-92527/v1
2020
Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd AR; Martinello M; Bull RA; Group COSINS, Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2, , http://dx.doi.org/10.2139/ssrn.3732365
Garcia Valtanen P; Hope CM; Masavuli MG; Yeow AEL; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Gummow J; Ferguson C; O’Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Chuan K-L; Beard M; Weiskopf D; Sette A; Bull RA; Barry SC; Grubor-Bauk B, 'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19, , http://dx.doi.org/10.2139/ssrn.3859298

Development of a human tonsil organoid model to study human disease. CI Abayasingam. Triple I Clinical Academic Group Seed. 2023. $75,000.